Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)
NCT01554176 · Merck Sharp & Dohme LLC · PHASE2 · terminated · last registry update 2018-11-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low Enrollment” | – | Registry record, Merck Sharp & Dohme LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HCRTR2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-11-01Results posted on the registry: Henry Ford Health System, Suvorexant 10 mg + Suvorexant 20 mg (NCT03312517)
- 2019-10-16Results posted on the registry: Merck Sharp & Dohme LLC, Suvorexant + Placebo (NCT02750306)
- 2019-08-05Results posted on the registry: Jichi Medical University, suvorexant (NCT02849184)
- 2019-07-05Phase 3 first posted: Eisai Inc., LEM 5 mg + LEM 10 mg (NCT04009577)
- 2018-09-21Phase 3 first posted: Idorsia Pharmaceuticals Ltd., Daridorexant 10 mg + Daridorexant 25 mg (NCT03679884)
- 2018-07-02Phase 3 first posted: Idorsia Pharmaceuticals Ltd., Daridorexant (NCT03575104)
- 2018-06-04Phase 3 first posted: Idorsia Pharmaceuticals Ltd., Daridorexant 25 mg + Daridorexant 50 mg (NCT03545191)
- 2018-01-26Phase 3 first posted: Milton S. Hershey Medical Center, Suvorexant 20 mg (NCT03412591)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision